Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab plus chemotherapy in pediatric and young adult relapsed/refractory ALL/lymphoblastic lymphoma
2017-003377-34Phase 2Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by Janssen Pharmaceutical. Primary endpoint: Complete response (CR) rate. Status: unknown.
02
Drugs
daratumumab
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on 2017-003377-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003377-34.